Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection

Hepatology Research

Volumn 44, Issue 14, 2014, Pages E360-E367

  Miura, Mika ^a   Maekawa, Shinya ^a   Sato, Mitsuaki ^a   Komatsu, Nobutoshi ^a   Tatsumi, Akihisa ^a   Takano, Shinichi ^a   Amemiya, Fumitake ^a   Nakayama, Yasuhiro ^a   Inoue, Taisuke ^a   Sakamoto, Minoru ^a   Enomoto, Nobuyuki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Deep sequencing; Hepatitis C virus; NS5A inhibitor; Resistance

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; DACLATASVIR; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 28B; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 1B; HOST; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PYROSEQUENCING; RELAPSE; TREATMENT RESPONSE;

EID: 84918525841     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12316     Document Type: Article

References (28)

1. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (Suppl 1): S88-100.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54 (4): 1433-1444.
3. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 2011; 140 (3): 1032-1042.
4. Lok AS, Gardiner DF, Lawitz E etal. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366 (3): 216-224.
5. Pol S, Ghalib RH, Rustgi VK etal. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12 (9): 671-677.
6. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54 (9): 3641-3650.
7. Fridell RA, Wang C, Sun JH etal. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54 (6): 1924-1935.
8. Karino Y, Toyota J, Ikeda K etal. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646-654.
9. Suzuki Y, Ikeda K, Suzuki F etal. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-662.
10. Chayama K, Takahashi S, Toyota J etal. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55 (3): 742-748.
11. Londono MC, Lens S, Forns X. Interferon free regimens for the "difficult-to-treat": are we there? J Hepatol 2013; 58: 643-645.
12. Hiraga N, Imamura M, Abe H etal. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 2011; 54 (3): 781-788.
13. Akuta N, Suzuki F, Seko Y etal. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. J Med Virol 2013; 85 (6): 1028-1036.
14. McPhee F, Hernandez D, Yu F etal. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013; 58 (3): 902-911.
15. Nagayama K, Kurosaki M, Enomoto N etal. Time-related changes in full-length hepatitis C virus sequences and hepatitis activity. Virology 1999; 263 (1): 244-253.
16. Miura M, Maekawa S, Kadokura M etal. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int 2012; 6 (1): 386-396.
17. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48 (6): 372-380.
18. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334 (2): 77-81.
19. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008; 48 (1): 38-47.
20. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
21. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41 (10): 1100-1104.
22. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41 (10): 1105-1109.
23. Miura M, Maekawa S, Takano S etal. Deep sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression. J Virol 2013; 87: 12541-12551.
24. Gates AT, Sarisky RT, Gu B. Sequence requirements for the development of a chimeric HCV replicon system. Virus Res 2004; 100 (2): 213-222.
25. Suzuki F, Sezaki H, Akuta N etal. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012; 54 (4): 352-354.
26. Maekawa S, Sakamoto M, Miura M etal. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology 2012; 56 (5): 1611-1621.
27. Friborg J, Levine S, Chen C etal. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother 2013; 57 (3): 1312-1322.
28. Kurosaki M, Tanaka Y, Nishida N etal. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54 (3): 439-448.